Mirae Asset Global Investments Co. Ltd. Purchases 838 Shares of Haemonetics Co. (NYSE:HAE)

Mirae Asset Global Investments Co. Ltd. grew its position in shares of Haemonetics Co. (NYSE:HAE) by 3.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,874 shares of the medical instruments supplier’s stock after acquiring an additional 838 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Haemonetics were worth $1,956,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Stifel Financial Corp raised its stake in Haemonetics by 2.5% in the first quarter. Stifel Financial Corp now owns 4,891 shares of the medical instruments supplier’s stock worth $405,000 after buying an additional 119 shares in the last quarter. Knights of Columbus Asset Advisors LLC raised its stake in Haemonetics by 1.3% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 10,005 shares of the medical instruments supplier’s stock worth $896,000 after buying an additional 128 shares in the last quarter. Meeder Asset Management Inc. raised its stake in Haemonetics by 65.2% in the fourth quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 135 shares in the last quarter. Metropolitan Life Insurance Co NY raised its stake in Haemonetics by 4.5% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 3,202 shares of the medical instruments supplier’s stock worth $252,000 after buying an additional 138 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its holdings in Haemonetics by 21.7% in the second quarter. Parkside Financial Bank & Trust now owns 786 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 140 shares during the period. 99.67% of the stock is owned by institutional investors.

Haemonetics Trading Down 2.7 %

NYSE:HAE opened at $81.24 on Friday. The company’s 50 day moving average price is $78.97 and its 200-day moving average price is $82.73. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $95.26. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The stock has a market cap of $4.13 billion, a price-to-earnings ratio of 33.02, a PEG ratio of 2.01 and a beta of 0.36.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The company had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. During the same quarter last year, the company posted $0.85 earnings per share. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. On average, equities research analysts forecast that Haemonetics Co. will post 3.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on HAE shares. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Barrington Research reiterated an “outperform” rating and set a $105.00 price target on shares of Haemonetics in a report on Friday, April 12th. Finally, TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.